Volume 25, No 3, Mar 2015
ISSN: 1001-0602
EISSN: 1748-7838 2018
impact factor 17.848*
(Clarivate Analytics, 2019)
Volume 25 Issue 3, March 2015: 271-272
RESEARCH HIGHLIGHTS
Regenerative medicine: targeted genome editing in vivo
Lixia Wang1, Jun Wu2, Weiwei Fang3, Guang-Hui Liu1,4,5 and Juan Carlos Izpisua Belmonte2
1National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
2Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA
3Beijing Hospital of the Ministry of Health, Beijing 100730, China
4Beijing Institute for Brain Disorders, Beijing 100069, China
5Center for Molecular and Translational Medicine, Beijing 100101, China
Correspondence: Guang-Hui Liu, E-mail: ghliu@ibp.ac.cn; Juan Carlos Izpisua Belmonte(belmonte@salk.edu)
The CRISPR/Cas system has proven to be a powerful gene editing tool both in vitro and
in vivo. A recent flurry of studies of
in vivo gene editing using the CRISPR/Cas system bring bright prospects in creating animal models and targeted gene therapy of human genetic diseases.
10.1038/cr.2015.11
FULL TEXT | PDF
Browse 1964
